Quantification of burden at the lesion-level can be undertaken using any number of different biomarkers, including SUVmax, SUVmean, SUVpeak (as recommended by the PERCIST criteria) and volume (which is implicitly incorporated into patient level frameworks such as RECIP 1.0, which requires a whole-body measurement of PSMA-positive tumour volume), among many others15,20,24,29. This evidence concerns the gene FOLH1 and neoplasm.